At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Not Yet Opened 01-09 16:00:00 EST
0.2420
+0.0085
+3.64%
盘后0.2450
+0.0030+1.24%
19:02 EST
High0.2471Low0.2301Vol258.32K
Open0.2390D1 Closing0.2335Amplitude7.28%
Mkt Cap6.72MTradable Cap6.42MTotal Shares27.78M
T/O61.99KT/O Rate0.97%Tradable Shares26.54M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Adial Pharmaceuticals Director James W. Newman Jr. Resigns
Reuters  ·  01-07
Adial Pharmaceuticals Director James W. Newman Jr. Resigns
Adial Pharmaceuticals Inc. Announces Date for Upcoming Special Stockholders Meeting
Reuters  ·  2025-12-24
Adial Pharmaceuticals Inc. Announces Date for Upcoming Special Stockholders Meeting
Adial Pharmaceuticals announces $2.86M warrant inducement transaction
TIPRANKS  ·  2025-11-26
Adial Pharmaceuticals announces $2.86M warrant inducement transaction
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
GlobeNewswire  ·  2025-11-26
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating
TIPRANKS  ·  2025-11-19
Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  2025-11-17
Calendar of U.S. Earnings Expected in the Week Ahead
Adial Pharmaceuticals reports Q3 net loss of $1.8 million
Reuters  ·  2025-11-14
Adial Pharmaceuticals reports Q3 net loss of $1.8 million
Adial Pharmaceuticals Q3 Net Income USD -1.8 Million
THOMSON REUTERS  ·  2025-11-14
Adial Pharmaceuticals Q3 Net Income USD -1.8 Million
Adial Pharmaceuticals: Implementing FDA's Recommendations Based on Eop2 Meeting, to Advance Ad04 Toward Phase 3 Development
THOMSON REUTERS  ·  2025-11-14
Adial Pharmaceuticals: Implementing FDA's Recommendations Based on Eop2 Meeting, to Advance Ad04 Toward Phase 3 Development
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  2025-11-14
Calendar of U.S. Earnings Expected in the Week Ahead
Adial Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Reuters  ·  2025-11-07
Adial Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GlobeNewswire  ·  2025-10-17
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating
TIPRANKS  ·  2025-10-11
Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating
Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing
TIPRANKS  ·  2025-10-09
Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing
Adial Pharmaceuticals Raised to Buy From Hold by Maxim Group
Dow Jones  ·  2025-09-30
Adial Pharmaceuticals Raised to Buy From Hold by Maxim Group
Adial Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold
THOMSON REUTERS  ·  2025-09-30
Adial Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold
Adial Pharmaceuticals upgraded to Buy from Hold at Maxim
TIPRANKS  ·  2025-09-30
Adial Pharmaceuticals upgraded to Buy from Hold at Maxim
Adial Pharmaceuticals Advances AD04 with FDA Support
TIPRANKS  ·  2025-09-16
Adial Pharmaceuticals Advances AD04 with FDA Support
Adial Pharmaceuticals Provides Business Update Following Favorable Comments From FDA End-of-Phase 2 (Eop2) Meeting for Ad04
THOMSON REUTERS  ·  2025-09-16
Adial Pharmaceuticals Provides Business Update Following Favorable Comments From FDA End-of-Phase 2 (Eop2) Meeting for Ad04
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
GlobeNewswire  ·  2025-09-16
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Introduction

Company Name.
Adial Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Issue price:
--